Schedule 4 medicine

Definition

In Australia, therapeutic goods are classified into different schedules based on the level of control and safety monitoring required. Schedule 4 medicines (also called prescription medicines or prescription-only medicines) are products that require an initial examination and diagnosis by a healthcare practitioner before supply. These medicines can only be dispensed by a pharmacist on receipt of a written or electronic prescription from an authorized practitioner (doctor, dentist, veterinarian, etc.). Schedule 4 classification indicates that the medicine carries a risk of harmful effects if used without professional supervision, or that its use requires monitoring. Many peptide compounds investigated in research and clinical contexts are Schedule 4 medicines in Australia because they are potent biological compounds with significant physiological effects that require medical oversight. The TGA assigns a schedule to each registered product as part of the approval process.

The Australian Poisons Standard establishes the scheduling system, which includes Schedule 1 (least restricted, over-the-counter) through Schedule 10 (prohibited). Schedule 4 falls in the middle-to-higher restriction level. A prescription for a Schedule 4 medicine typically allows one or more repeats (refills) depending on the prescriber's authorization. Pharmacists have limited authority to modify a prescription (such as reducing quantity) but generally cannot supply a Schedule 4 medicine without a valid prescription. The requirement for prescribing ensures that use is appropriately indicated, monitored for adverse effects, and coordinated with the patient's other medications.

Classification as Schedule 4 does not necessarily imply that a medicine is unsafe; rather, it reflects that proper medical assessment is necessary before use. Many Schedule 4 medicines have extensive safety data and long histories of therapeutic use but are scheduled because their effects are significant and require individualization of dosing and monitoring. For research-only peptide compounds that have not been approved for therapeutic supply, they are typically not assigned a schedule and fall outside the regulatory framework unless supplied under the Special Access Scheme or research protocols.